Interní Med. 2016; 18(2): 103-106 | DOI: 10.36290/int.2016.025

Canagliflozin-inhibitor SGLT2 in diabetes mellitus therapy

MUDr.Alena Adamíková, Ph.D.
Diabetologické centrum IK KNTB, a. s., Zlín

Canagliflozin-inhibitor SGLT2 ranks among the selectively acting inhibitors of the sodium-glucose co-transporter SGLT2. It reduces

glycaemia by blocking reabsorption of glucose in the kidneys and by lowering the renal threshold. Increased glycosuria is linked

to reduction of weight during energy losses and lowering of blood pressure at osmotic diuresis. Transient inhibition of SGLT1 with

impact on enteric absorption of glucose is assumed. During inhibition of SGLT2 there exists a lower risk of hypoglycaemia as the

extent of excretion of glucose in the urine diminishes on decrease of glycaemia. Reduction of glycaemia at SGLT2 inhibition is

independent of insulin and thus provides therapeutic possibilities for a broad spectrum of diabetic patients.

Keywords: canagliflozin, SGLT2, reabsorption of glucose, renal threshold

Published: May 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adamíková A. Canagliflozin-inhibitor SGLT2 in diabetes mellitus therapy. Interní Med. 2016;18(2):103-106. doi: 10.36290/int.2016.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Valentine V, Hinnen D. Cliniccal implications of canagliglozin tretment in patients with type 2 diabetes. Clinical.diabetesjournals.org. 2015; 33(1): 5-13. Go to original source...
    2. SPC Invokana. http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002649/WC500156456.pdf
    3. Liang Y, Arakawa K, Ueta K, et al. Effect of kanagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012;7: e30555. Go to original source... Go to PubMed...
    4. Česká diabetologická společnost. Doporučený postup péče o diabetes mellitus 2. typu. www.diab.cz.
    5. Stenlöf K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014; 30: 163-175. Go to original source... Go to PubMed...
    6. Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patinets with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950. Go to original source... Go to PubMed...
    7. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013; 67: 1267-1282. Go to original source... Go to PubMed...
    8. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 2013; 36: 2508-2515. Go to original source... Go to PubMed...
    9. Lavalle-Gonzales F, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582-2592. Go to original source...
    10. Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014; 16: 467-477. Go to original source...
    11. Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013; 41: 72-84. Go to original source... Go to PubMed...
    12. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-473. Go to original source... Go to PubMed...
    13. Matthews D, Fulcher G, Perkovic V, et al. Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), addend-on to insulin therapy +/- oral agents in type 2 diabetes (T2D) (Abstract). Diabetologia 2012; 55: A764. Go to original source...
    14. Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2015; 38(3): 403-411. Go to original source...
    15. Invokana and invokamet (canagliflozin): drug safety communication-new infomation on bone fracture risk and decreased bone mineral density. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm461876.htm.
    16. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38: 1687-1693. Go to original source...
    17. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. Am Heart J 2013; 166(2): 217-233. Go to original source...
    18. Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin used in conjuction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial. Diabetes Ther 2015; 6(3): 289-302. Go to original source...
    19. Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin when used in conjuction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab 2015; doi: 10.1111/dom.12589. [Epub ahead of print]. Go to original source...
    20. Saroka RM, Kane MP, Busch RS, et al. SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM. Endocr Pract 2015; 21(12): 13-15-22. Doi: 10.4158/EP15877.OR. Epub 2015 Aug 26. Go to original source...
    21. Blonde L, Woo V, Mathieu C, et al. Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Curr Med Res Opin 2015; 31(11): 1993-2000. Doi: 10.1185/03007995.2015.1082991. Epub 2015 Sep 28. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.